Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02095145 · ClinicalTrials.gov registry record · Phase 2
Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
A Phase 2 study of Stage IIB Prostate Cancer AJCC v7 and Stage I Prostate Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 4
- Study locations
NCT02095145 is a Phase 2 study of Stage IIB Prostate Cancer AJCC v7 and Stage I Prostate Cancer AJCC v7 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 38 participants, below the 179-participant average among 3 other Stage IIB Prostate Cancer AJCC v7 trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02095145, a Phase 2 study of Stage IIB Prostate Cancer AJCC v7 and Stage I Prostate Cancer AJCC v7, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment plan. The use of pomegranate-extract pill may slow disease progression in patients with localized prostate cancer.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Pomegranate-Extract Pill
Study Locations (4)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Minnesota
- University of Minnesota/Masonic Cancer Center - Minneapolis
Texas
- Urology San Antonio Research PA - San Antonio
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-05-08 |
| Est. Completion | 2019-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02095145
The ClinicalTrials.gov registry entry for NCT02095145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 3 other Stage IIB Prostate Cancer AJCC v7 trials with a reported enrollment target (79% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Stage IIB Prostate Cancer AJCC v7 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02095145 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT02095145 about?
NCT02095145 is a clinical study titled "Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance". This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment plan. The use of pomegranate-extract pill may slow disease progression...
What is the current status of trial NCT02095145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2014-05-08. Estimated completion is 2019-09-26.
What conditions does trial NCT02095145 study?
This clinical trial studies the following conditions: Stage IIB Prostate Cancer AJCC v7, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, PSA Level Less Than or Equal to Fifteen.
What interventions are being tested in trial NCT02095145?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Pomegranate-Extract Pill (DRUG).
Who is sponsoring clinical trial NCT02095145?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02095145 being conducted?
This trial has 4 study locations across Massachusetts, Minnesota, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIB Prostate Cancer AJCC v7
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
RECRUITING
-
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
COMPLETED · NA
Explore more on PlainTrial
Stage IIB Prostate Cancer AJCC v7
All registered trials for this condition
Stage I Prostate Cancer AJCC v7
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.